Merck CEO expects accelerated production of cancer vaccines in collaboration with Moderna
MRNA Moderna Inc
$226.30 +4.65%
View chart & analysis → - 1The Merck CEO predicts that the manufacturing period for innovative cancer vaccines developed with Moderna will shorten over time.
- 2Shortening the current six-week vaccine manufacturing timeline would allow for delivery to more patients.
- 3Merck is preparing for December 2028, when the core US compound patent for Keytruda expires.
So what's the key point?
The time required to make cancer vaccines being developed by Merck and Moderna is expected to decrease. This is in preparation for the expiration of a key drug patent in December 2028.
Source CNBC · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.